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Viral hepatitis is an important problem of modern 
medical science and practical health care in all countries of 
the world. Already, the total number of patients with viral 
hepatitis in the world is 14-15 times higher than the number 
of HIV-infected people. Viral hepatitis is 50-100 times 
more contagious than HIV. In recent years there has been 
a tendency for an increase in cases of chronic forms of the 
disease. According to WHO experts, about 150 million 
people suffer from chronic viral hepatitis C (CHC), and 
350,000 die annually as a result of liver damage by the 
hepatitis C virus (HCV) [1]. The incidence and mortality 
rate due to CHC is progressively increasing on the planet 
and, according to experts, will double by 2015-2020 [2, 3]. 
Ukraine is one of the countries with medium 
prevalence of CHC – about 3% of citizens are infected. In 
terms of the degree of negative impact on the health of the 
population and the scale of the incidence of CHC in 
Ukraine, it is dominant in the structure of infectious 
pathology, together with influenza and acute infectious 
diseases of the upper respiratory tract. Nearly 24,786 
patients are waiting for treatment in Ukraine [4]. 
CHC has become a treatable disease with the use 
of antiviral drugs (> 95%) [5, 6]. To date, for the 
pharmacotherapy of CHC, a combination of pegylated 
interferon (PEG-IFN) with Ribavirin and direct-acting 
antivirals (DAAs) are used. Moreover, most recently, the 
recommendations of the American Association for the 
Study of Liver Diseases (AASLD) and the American 
Society of Infectious Diseases (IDSA) removed the 
priorities and treatment is now highly recommended for all 
patients with CHC [7, 8]. 
Relatively recently, a number of DAAs have been 
developed for the specific effect on various hepatitis C 
virus replication sites. These include: NS3/4A protease 
inhibitors (Boceprevir, Voxilaprevir, Telaprevir, 
Simeprevir, Grazoprevir, Glecaprevir); NS5B protease 
inhibitors (Sofosbuvir, Dasabuvir); NS5A protease 
inhibitors (Ledipasvir, Daclatasvir, Ombitasvir, Elbasvir, 
Velpatasvir, Pibrentasvir) [9]. 
To evaluate the effectiveness of treatment, the 
following criteria are distinguished [10]: 
- The answer at the end of treatment means that after the 
end of HCV treatment, the viral load (VL) is not 
determined. 
- A stable virologic response (SVR) means that the VL 
became undetectable during treatment and remained 
undetectable for 12 weeks (SVR-12) or 24 weeks (SVR-
24) after treatment. SVR-12 increases the chances of SVR-
24, since if the HCV returns, then this usually happen 
within 12 weeks. SVR -24 is an indicator of cure. 
- A quick virologic response (QVR) means that after 4 
weeks of treatment, no HCV has been detected in the 
patient’s blood. QVR significantly increases the chances of 
a successful outcome, but even without a QVR, the patient 
still has a chance of recovery at the end of the full course.  
- An early virologic response (ERV) means that after 12 
weeks of treatment, VL decreased by 99% from the level 
that was before pharmacotherapy. 
- Virologic breakthrough: VL became undetectable at one 
control point of treatment, but later became detectable 
again. In this situation, a second VN test is needed to 
ensure that it is detectable. If VL is determined, stop 
treatment is needed. 
- A partial response or lack of a virologic response is 
characterized by a decrease in VL, but it did not become 
undetectable after 24 weeks of treatment. 
- A zero response is characterized by a slight decrease in 
VL or the absence of a decrease in VL during treatment. 
- Relapse of HCV is considered to be a condition when 
after the end of treatment HCV is determined in the blood. 
Approximately 18% of people who have been treated have 
a relapse. HCV usually appears in the blood 12 weeks after 
the end of treatment. 
Patients who failed to achieve SVR are given a 
second course of treatment. The decision on this is based 
on the following main positions: the nature of the previous 
response, the type of previous therapy and the potential for 
a new type of treatment, the severity of liver damage, the 
genotype of the virus and the presence of other prognostic 
factors and tolerance to previous therapy. 
Pharmacotherapy of СHC using a combination of 
PEG-IFN and ribavirin has a relatively high efficiency, but 
it depends on the genotype of the HCV. According to the 
meta-analysis, which included five studies with a total 
number of patients 20014 patients receiving 
pharmacotherapy for CHC with a combination of PEG-IFN 
and ribavirin, SVR comprised 53-73%, depending on the 
HCV genotype. SVR with EVR was 46-85% also 
depending on the HCV genotype. SVR without ERV 
amounted to 10-33% [11]. Therefore, the use of DAAs is a 
priority in pharmacotherapy of chronic hepatitis C. A 
number of studies have shown 100% efficacy of CHC 
pharmacotherapy using 3D therapy based on DAAs 
(combination of Ombitasvir/Paritaprevir, reinforced by 
Ritonavir) in combination (Dasabuvir) or a combination of 
Sofosbuvir, Ledipasvira and INF for 12 weeks [12, 13]. 
 
Material & methods 
 The article analyzes the recommendations of 
the American Society of Infectious Diseases (IDSA) and 
the American Association for the Study of Liver Diseases 
(AASLD), in collaboration with the US International Anti-
Virus Society (IAS-USA) [8, 14], as well as the WHO 
recommendation [15] for repeated pharmacotherapy of 
CHC in patients who failed to achieve SVR. 
 
Results & discussion 
 To date, for repeated pharmacotherapy of CHC 
in patients receiving treatment without achieving a SVR, 
the following re-treatment regimens are recommended 
depending on the genotype of the HCV. 
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Re-treatment regimens of CHC caused by HCV 
genotype 1a and 1b in patients treated with PEG-IFN and 
Ribavirin:  
• A daily fixed-dose combination of Elbasvir (50 
mg)/Grazoprevir (100 mg) for 12 weeks if patients have 
not found resistance to protein NS5A for Elbasvir;  
• A daily fixed-dose combination of Glacaprevir (300 
mg)/Pibrentasvir (120 mg) for 8 weeks; 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Ledipasvir (90 mg) or Velpatasvir (100 mg) for 12 
weeks.  
The last two regimens are recommended in patients treated 
with NS3 protease inhibitors (Telaprevir, Boceprevir or 
Simeprevir) plus PEG-IFN in combination with Ribavirin. 
Alternative re-treatment regimens: 
• A daily-dose of combination Sofosbuvir (400 
mg)/Simeprevir (150 mg) or Daclatasvir (60 mg) for 12 
weeks; 
• A daily fixed-dose combination of Elbasvir (50 
mg)/Grazoprevir (100 mg) with Ribavirin based on body 
weight for 16 weeks, if patients have not found 
substitutions associated with resistance to protein NS5A 
for Elbasvir. In the case of a high level of resistance to the 
NS5A protease inhibitor for Elbasvir, it is necessary to 
extend the course of treatment up to 16 weeks. 
Re-treatment regimens for CHC caused by HCV genotype 
1 in patients treated with Sofosbuvir but not treated with 
NS5A protease inhibitors: 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg)/Voxilaprevir (100 mg) for 12 
weeks for patients with genotype 1a; 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg) or 12 weeks for patients with 
genotype 1b; 
• A daily fixed-dose of the combination of Glacaprevir 
(300 mg)/Pibrentasvir (120 mg) for 12 weeks, regardless 
of the HCV subtype (1a or 1b). 
 Alternative re-treatment regimen is a daily 
fixed-dose of the combination of Ledipasvir (90 
mg)/Sofosbuvir (400 mg) in combination with Ribavirin 
based on body weight, with the exception of cases of 
treatment failure with Simeprevir, for 12 weeks. 
Recommended re-treatment regimens for CHC caused by 
HCV genotype 2: 
• A daily fixed-dose combination of Glacaprevir (300 
mg)/Pibrentasvir (120 mg) for 8 weeks; 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg) for 12 weeks. 
Alternative treatment regimen is a daily dose of 
combination Daclatasvir (60 mg) and Sofosbuvir (400 
mg) for 12 weeks. 
Recommended re-treatment regimen for CHC caused by 
HCV genotype is a daily fixed-dose combination of 
Sofosbuvir (400 mg)/Velpatasvir (100 mg) for 12 weeks.  
Alternative re-treatment regimens: 
•A daily dose of Daclatasvir (60 mg) in combination with 
Sofosbuvir (400 mg) for 12 weeks; 
• A daily fixed-dose combination of Glacaprevir (300 
mg)/Pibrentasvir (120 mg) for 16 weeks; 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg)/Voxilaprevir (100 mg) for 12 
weeks when there is a mutation of the NS5A Y93H gene 
when determining resistance to NS5A protease inhibitors. 
Recommended re-treatment regimens for CHC caused by 
HCV genotype 4: 
 • A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg) or Ledipasvir (90 mg) for 12 
weeks;  
• A daily fixed-dose combination of Glacaprevir (300 
mg)/Pibrentasvir (120 mg) for 8 weeks;  
• A daily fixed-dose combination of Elbasvir (50 
mg)/Grazoprevir (100 mg) for 12 weeks for patients who 
have had a virologic relapse after previous treatment 
combination PEG-IFN/Ribavirin. 
Alternative re-treatment regimens: 
•A daily fixed-dose combination of Paritaprevir (150 
mg)/Ritonavir (100 mg)/Ombitasvir (25 mg) and Ribavirin 
based on weight for 12 weeks; 
• A daily fixed-dose combination of Elbasvir (50 
mg)/Grazoprevir (100 mg) and Ribavirin based on body 
weight for 16 weeks. 
Recommended re-treatment regimens for CHC caused by 
HCV genotype 5-6 in patients treated with PEG-IFN in 
combination with Ribavirin: 
• A daily fixed-dose combination of Glycaprevir (300 
mg)/Pibrentasvir (120 mg) for 8 weeks; 
• A daily fixed-dose combination Ledipasvir (90 
mg)/Sofosbuvir (400 mg) for 12 weeks; 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg) for 12 weeks. 
Recommended re-treatment regimen for CHC caused by 
HCV genotype 5-6 in patients treated with DAAs 
(including drugs that are NS5A protease inhibitors): 
• A daily fixed-dose combination of Sofosbuvir (400 
mg)/Velpatasvir (100 mg)/Voxilaprevir (100 mg) for 12 
weeks. 
An important problem during pharmacotherapy of 
patients with CHC is resistance to antiviral therapy. The 
amino acid polymorphism of NS3, NS5A and NS5B viral 
proteins in different HCV genotypes and subtypes, as well 
as the same strains of genotypes and subtypes that reduce 
DAAs efficacy, is referred to as resistance-related variants 
(RRV). However, antiviral therapy fails only when RRV is 
combined with other factors and features of the patient's 
body, decreased sensitivity to antiviral therapy, or 
insufficient duration of therapy [12, 16, 17]. As seen in the 
recommendations for recurrent CHC pharmacotherapy, 
possible resistance to the protease inhibitor NS5A for 
Elbasvir, as well as to the NS3 protease inhibitors for 
Telaprevir, Boceprevir, or Simeprevir was considered. 
The results obtained from published sources 
indicate that current strategies for recurrent 
pharmacotherapy of CHC patients in most cases of 
unsuccessful pre-treatment allow the achievement of SVR 
using DAAs during re-treatment, including those regimens 
that have efficacy in resistance-associated variants. 
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Introduction. According to WHO experts, about 150 
million people suffer from chronic viral hepatitis C 
(CHC), and 350,000 die annually as a result of liver 
damage by the hepatitis C virus (HCV). Ukraine is one of 
the countries with medium prevalence of CHC – about 
3% of citizens are infected. CHC has become a treatable 
disease with the use of antiviral drugs (> 95%). To date, 
for the pharmacotherapy of CHC, a combination of 
pegylated interferon (PEG-IFN) with ribavirin and direct-
acting antivirals (DAAs) are used. Pharmacotherapy of 
СHC using a combination of PEG-IFN and ribavirin has a 
relatively high efficiency, but it depends on the genotype 
of the HCV. Therefore, the use of DAAs is a priority in 
pharmacotherapy of chronic hepatitis C. Patients who 
failed to achieve sustained virologic response (SVR) are 
given a second course of treatment (retreatment). The 
decision on this is based on the following main positions: 
the nature of the previous response, the type of previous 
therapy and the potential for a new type of treatment, the 
severity of liver damage, the genotype of the virus and the 
presence of other prognostic factors and tolerance to 
previous therapy. Material & methods. The article 
analyzes the recommendations of the American Society of 
Infectious Diseases (IDSA) and the American Association 
for the Study of Liver Diseases (AASLD), in 
collaboration with the US International Anti-Virus 
Society (IAS-USA), as well as the WHO recommendation 
for repeated pharmacotherapy of CHC in patients who 
failed to achieve SVR. Results & discussion. To date, for 
re-treatment of CHC in patients receiving treatment 
without achieving a SVR, the different re-treatment 
regimens are recommended depending on the genotype of 
the HCV. An important problem during pharmacotherapy 
of patients with CHC is resistance to antiviral therapy. 
The amino acid polymorphism of NS3, NS5A and NS5B 
viral proteins in different HCV genotypes and subtypes, 
as well as the same strains of genotypes and subtypes that 
reduce DAAs efficacy, is referred to as resistance-related 
variants (RRV). However, antiviral therapy fails only 
when RRV is combined with other factors and features of 
the patient's body, decreased sensitivity to antiviral 
therapy, or insufficient duration of therapy. As seen in the 
recommendations for recurrent CHC pharmacotherapy, 
possible resistance to the protease inhibitor NS5A and to 
the NS3 protease inhibitors was considered. Conclusion. 
The results obtained from published sources indicate that 
current strategies for recurrent pharmacotherapy of CHC 
patients in most cases of unsuccessful pre-treatment allow 
the achievement of SVR using DAAs during re-treatment, 
including those regimens that have efficacy in resistance-
associated variants. 
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